



**BlueCross  
BlueShield**

Federal Employee Program.

## **QBREXZA (glycopyrronium)**

### **RATIONALE FOR INCLUSION IN PA PROGRAM**

#### **Background**

Qbrexza (glycopyrronium) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, Qbrexza inhibits the action of acetylcholine on sweat glands, which reduces sweating (1).

#### **Regulatory Status**

FDA-approved indication: Qbrexza is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older (1).

Qbrexza should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Patients should be instructed to discontinue use immediately and consult a physician should any of these signs or symptoms develop (1).

In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as Qbrexza. Patients using Qbrexza should be advised to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions (1).

Transient blurred vision may occur with use of Qbrexza. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery or performing hazardous work until the symptoms have resolved (1).

The safety and efficacy of Qbrexza have not been established in pediatric patients under 9 years of age (1).

#### **Summary**

Qbrexza (glycopyrronium) is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. In hyperhidrosis, Qbrexza inhibits the action of



**BlueCross  
BlueShield**

Federal Employee Program.

**QBREXZA  
(glycopyrronium)**

acetylcholine on sweat glands, which reduces sweating. The safety and efficacy of Qbrexza have not established in pediatric patients under 9 years of age (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Qbrexza while maintaining optimal therapeutic outcomes.

**References**

1. Qbrexza [package insert]. Scottsdale, AZ: Journey Medical Corporation; November 2022.